Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months (ASD-CXCR4)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01686685|
Recruitment Status : Recruiting
First Posted : September 18, 2012
Last Update Posted : April 21, 2015
Preterm children are at increased risk for autism spectrum disorders, with an estimated rate of 10%. In the US, about 1 in 8 pregnancies ends with a premature birth. Therefore, individuals with ASD who were born prematurely form a substantial body of children diagnosed with ASD.
Premature birth confers an insult to the newborn at a neurologically vulnerable stage. Prematurity associated changes in oxygen tension can be detrimental to developing organs, the brain being one of the most rapidly developing organs in the second half of the pregnancy. Changes in oxygen tension mediate activation of proteins that change the course of cell development.
In this study, we plan to measure changes in the expression of 3 proteins that may be affected by changes in oxygen level at birth. We will study the interaction between the proteins' levels in the first few days after premature birth with a diagnosis of ASD at 2 years of age. The proteins are:
- VEGF (Vascular Endothelial Growth Factor), a protein that takes part in creating new blood vessels during embryonic development.
- Hypoxia-inducible factor -1(HIF-1), a key protein that coordinates expression of different genes, many with developmentally critical functions.
- CXCR4, a cell surface protein that is activated by SDF-1. SDF- 1 is a molecule that regulates migration of cells to their target destination during embryonic life. CXCR4 is expressed in areas of the brain and on cells that are known to be associated with ASD.
We hypothesis that changes in oxygen tension in premature babies initiates a cascade of events that lead to changes in cell mobility via abnormal CXCR4 expression. This change leads to abnormal neurodevelopment.
The investigators' primary aim is to find if there is a correlation between postnatal levels of expression of HIF-1, CXCR4 and VEGF and a diagnosis of autism at age 24 months. The investigators' secondary aim is to find if there is a correlation between postnatal levels of expression of HIF-1, CXCR4 and VEGF and a language or neurocognitive delay.
- Premature babies will be recruited in the first day post delivery.
- Blood samples will be collected at 3 time points during their hospitalization, and the expression of HIF-1, CXCR4 and VEGF will be determined.
- Infants will undergo a complete developmental evaluation at 18-24 months of age .
- Postnatal levels of HIF, CXCR4 and VEGF will be plotted against the results of the developmental evaluation.
|Condition or disease|
|Autism Spectrum Disorder Complication of Prematurity|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Study of Correlation Between Expression of Proteins That Are Essential for Embryonic Brain Development and Neurodevelopmental Outcomes at 2 Years of Age in Premature Infants.|
|Study Start Date :||September 2013|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||December 2018|
- Diagnosis of ASD at 24 months corrected age [ Time Frame: 30 months ]Participants will be screened at 18 and 24 months for autism using the MCHAT questionnaire all positive screens will be referred for a complete developmental evaluation by child psychologist and developmental pediatrician: History, assessment (ADOS) and clinical judgement based on DSM criteria
- Language or cognitive delay at 24 months corrected age [ Time Frame: 30 months ]Participants will be screened by questionnaires at 18 and 24 months. all positive screens will be referred for a full developmental evaluation using the Mullen Scales of Early learning
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01686685
|Contact: Michal Begin, MDemail@example.com|
|Contact: Hadas Lemberg, PhDfirstname.lastname@example.org|
|Hadassah Medical Center||Recruiting|
|Study Director:||Michal Begin, MD||Hadassah HMO|